Search

EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias

Dates: September 21-22, 2018
Location: Warsaw, Poland
Chairs: T Robak,  G Gaidano, I Hus

Following successful previous editions, EHA is coordinating the third two-day tutorial in close collaboration with the Polish Society of Hematology and Transfusion Medicine on “Myeloid and Lymphoid Leukemias”.…

Read more

Call for urgent action on medicine shortages in Europe

Medicine shortages are an increasing problem across Europe, posing a severe threat to patient outcomes and patient safety. In a new position paper the European Public Health Alliance (EPHA) presents nine recommendations for addressing the shortages crisis.

Read more

EHA-KCS Hematology Tutorial on Lymphoma and Multiple Myeloma

Dates: March 14-16, 2019
Location: Almaty, Kazakhstan
Chairs: G Gaidano, D Kaidarova
Co-chairs: S Gabbasova, B Afanasyev 

This meeting will be held in English and offer a simultaneous translation to Russian.

Read more

EHA-SLCH Hematology Tutorial on Myeloid Malignancies and MDS

Dates: February 8-9, 2019
Location: Colombo, Sri Lanka
Chairs: G Ossenkoppele, V Gunawardena, HW Goonasekera

After a successful first edition in 2017, EHA is organizing the second two-day tutorial in close collaboration with the Sri Lanka College of Haematologists (SLCH) on "Myeloid malignancies and MDS".…

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of the EHA

During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.

Read more

Great new opportunity for the YoungEHA community!

Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee

The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more